Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1978 1
1998 1
2001 2
2002 1
2007 1
2008 1
2010 3
2011 2
2012 1
2013 2
2014 1
2015 5
2016 5
2017 5
2018 9
2019 10
2020 23
2021 29
2022 20
2023 21
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. Among authors: de melo ac. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. Among authors: de melo ac. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Oza AM. Kristeleit R, et al. Among authors: de melo ac. Lancet Oncol. 2022 Apr;23(4):465-478. doi: 10.1016/S1470-2045(22)00122-X. Epub 2022 Mar 14. Lancet Oncol. 2022. PMID: 35298906 Clinical Trial.
Molecular landscape of Hereditary Melanoma.
Ribeiro Moura Brasil Arnaut J, Dos Santos Guimarães I, Evangelista Dos Santos AC, de Moraes Lino da Silva F, Machado JR, de Melo AC. Ribeiro Moura Brasil Arnaut J, et al. Among authors: de melo ac. Crit Rev Oncol Hematol. 2021 Aug;164:103425. doi: 10.1016/j.critrevonc.2021.103425. Epub 2021 Jul 7. Crit Rev Oncol Hematol. 2021. PMID: 34245855 Review.
An Update on Mucosal Melanoma: Future Directions.
Goldemberg DC, Thuler LCS, de Melo AC. Goldemberg DC, et al. Among authors: de melo ac. Acta Dermatovenerol Croat. 2019 Mar;27(1):11-15. Acta Dermatovenerol Croat. 2019. PMID: 31032785 Review.
Persistently positive SARS-CoV-2-specific IgM during 1-year follow-up.
Fonseca MHG, Silva MFS, Pinto ACMD, de Melo ACL, de Oliveira FCE, Araújo FMC, de Andrade LOM. Fonseca MHG, et al. Among authors: de melo acl. J Med Virol. 2022 Sep;94(9):4037-4039. doi: 10.1002/jmv.27822. Epub 2022 May 12. J Med Virol. 2022. PMID: 35505640 Free PMC article. No abstract available.
Implementation of a pharmacogenomic program in a Brazilian public institution.
Suarez-Kurtz G, Kovaleski G, Elias AB, Motta V, Wolch K, Emerenciano M, Mansur MB, Palladino AM, Accioly MT, Ferreira M, Gonçalves AA, de Melo AC. Suarez-Kurtz G, et al. Among authors: de melo ac. Pharmacogenomics. 2020 Jun;21(8):549-557. doi: 10.2217/pgs-2020-0016. Epub 2020 May 7. Pharmacogenomics. 2020. PMID: 32378980 Review.
Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome.
Guimarães GR, Maklouf GR, Teixeira CE, de Oliveira Santos L, Tessarollo NG, de Toledo NE, Serain AF, de Lanna CA, Pretti MA, da Cruz JGV, Falchetti M, Dimas MM, Filgueiras IS, Cabral-Marques O, Ramos RN, de Macedo FC, Rodrigues FR, Bastos NC, da Silva JL, Lummertz da Rocha E, Chaves CBP, de Melo AC, Moraes-Vieira PMM, Mori MA, Boroni M. Guimarães GR, et al. Among authors: de melo ac. Nat Commun. 2024 Jul 7;15(1):5694. doi: 10.1038/s41467-024-49916-4. Nat Commun. 2024. PMID: 38972873 Free PMC article.
Antitumor copper(II) complexes with hydroxyanthraquinones and N,N-heterocyclic ligands.
de Souza ÍP, de Melo ACC, Rodrigues BL, Bortoluzzi A, Poole S, Molphy Z, McKee V, Kellett A, Fazzi RB, da Costa Ferreira AM, Pereira-Maia EC. de Souza ÍP, et al. Among authors: de melo acc. J Inorg Biochem. 2023 Apr;241:112121. doi: 10.1016/j.jinorgbio.2023.112121. Epub 2023 Jan 4. J Inorg Biochem. 2023. PMID: 36696836
Cancer immunotherapy: the art of targeting the tumor immune microenvironment.
da Silva JL, Dos Santos ALS, Nunes NCC, de Moraes Lino da Silva F, Ferreira CGM, de Melo AC. da Silva JL, et al. Among authors: de melo ac. Cancer Chemother Pharmacol. 2019 Aug;84(2):227-240. doi: 10.1007/s00280-019-03894-3. Epub 2019 Jun 25. Cancer Chemother Pharmacol. 2019. PMID: 31240384 Review.
130 results